Literature DB >> 11697463

The development of beta-lactam antibiotics in response to the evolution of beta-lactamases.

S Y Essack1.   

Abstract

beta-Lactam antibiotics, viz., penicillin, penicillin derivatives, cephalosporins, cephamycins, carbapenems, monobactams. and monocarbams, are the most widely used of all antimicrobial classes by virtue of their high efficacy and specificity and the availability of several derivatives. The expression of one or several beta-lactamases (beta-lactam antibiotic-inactivating enzymes) represents the most widespread and the most clinically relevant resistance mechanism to these antibiotics. The development of beta-lactam antibiotics has thus been a continuous battle of the design of new compounds to withstand inactivation by the ever-increasing diversity of beta-lactamases. This article traces antibiotic development in response to the evolution of beta-lactamases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11697463     DOI: 10.1023/a:1012272403776

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  73 in total

1.  Mechanisms and clinical significance of resistance to new beta-lactam antibiotics.

Authors:  D M Livermore; M J Wood
Journal:  Br J Hosp Med       Date:  1990-10

Review 2.  Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics.

Authors:  A A Medeiros
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

Review 3.  The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics.

Authors:  I Chopra; J Hodgson; B Metcalf; G Poste
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Acinetobacter calcoaceticus: a nosocomial pathogen with an unusual seasonal pattern.

Authors:  H F Retailliau; A W Hightower; R E Dixon; J R Allen
Journal:  J Infect Dis       Date:  1979-03       Impact factor: 5.226

Review 5.  Classification of beta-lactamases.

Authors:  A Bauernfeind
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

6.  In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor.

Authors:  K Coleman; D R Griffin; J W Page; P A Upshon
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

7.  Point mutation in the pribnow box, the molecular basis of beta-lactamase overproduction in Klebsiella oxytoca.

Authors:  B Fournier; C Y Lu; P H Lagrange; R Krishnamoorthy; A Philippon
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

Review 8.  Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams.

Authors:  G A Jacoby
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

9.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

Review 10.  beta-Lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug
View more
  20 in total

1.  Structural study of phenyl boronic acid derivatives as AmpC beta-lactamase inhibitors.

Authors:  Donatella Tondi; Samuele Calò; Brian K Shoichet; Maria Paola Costi
Journal:  Bioorg Med Chem Lett       Date:  2010-04-09       Impact factor: 2.823

2.  Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations.

Authors:  Peter A Smith; Tucker C Roberts; Floyd E Romesberg
Journal:  Chem Biol       Date:  2010-11-24

3.  Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture.

Authors:  Donatella Tondi; Federica Morandi; Richard Bonnet; M Paola Costi; Brian K Shoichet
Journal:  J Am Chem Soc       Date:  2005-04-06       Impact factor: 15.419

4.  Species diversity and antibiotic resistance properties of Staphylococcus of farm animal origin in Nkonkobe Municipality, South Africa.

Authors:  Anthony A Adegoke; Anthony I Okoh
Journal:  Folia Microbiol (Praha)       Date:  2013-09-05       Impact factor: 2.099

5.  Crystal structure of a preacylation complex of the β-lactamase inhibitor sulbactam bound to a sulfenamide bond-containing thiol-β-lactamase.

Authors:  Elizabeth A Rodkey; Sarah M Drawz; Jared M Sampson; Christopher R Bethel; Robert A Bonomo; Focco van den Akker
Journal:  J Am Chem Soc       Date:  2012-09-26       Impact factor: 15.419

6.  Potential Influence of Regulation of the Food Value Chain on Prevalence and Patterns of Antimicrobial Resistance: the Case of Tilapia (Oreochromis niloticus).

Authors:  Hillary Adawo Onjong; Victor Ntuli; Joseph Wambui; Mercy Mwaniki; Patrick Murigu Kamau Njage
Journal:  Appl Environ Microbiol       Date:  2021-09-22       Impact factor: 4.792

Review 7.  Directed evolution and rational approaches to improving Streptomyces clavuligerus deacetoxycephalosporin C synthase for cephalosporin production.

Authors:  Kian-Sim Goo; Chun-Song Chua; Tiow-Suan Sim
Journal:  J Ind Microbiol Biotechnol       Date:  2009-03-07       Impact factor: 3.346

8.  Crystal structures of Pseudomonas aeruginosa GIM-1: active-site plasticity in metallo-β-lactamases.

Authors:  Pardha Saradhi Borra; Ørjan Samuelsen; James Spencer; Timothy R Walsh; Marit Sjo Lorentzen; Hanna-Kirsti S Leiros
Journal:  Antimicrob Agents Chemother       Date:  2012-12-03       Impact factor: 5.191

9.  Testing the Limitations of MD-Based Local Electric Fields Using the Vibrational Stark Effect in Solution: Penicillin G as a Test Case.

Authors:  Jacek Kozuch; Samuel H Schneider; Chu Zheng; Zhe Ji; Richard T Bradshaw; Steven G Boxer
Journal:  J Phys Chem B       Date:  2021-04-26       Impact factor: 2.991

10.  Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non-β-lactam-β-lactamase inhibitor.

Authors:  Mohammad Faheem; Md Tabish Rehman; Mohd Danishuddin; Asad U Khan
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.